These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31597207)

  • 41. Assessment of cost-effective changes to the current and potential provision of smoking cessation services: an analysis based on the EQUIPTMOD.
    Anraad C; Cheung KL; Hiligsmann M; Coyle K; Coyle D; Owen L; West R; de Vries H; Evers SM; Pokhrel S
    Addiction; 2018 Jun; 113 Suppl 1(Suppl Suppl 1):96-105. PubMed ID: 29430762
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
    Keating GM; Lyseng-Williamson KA
    Pharmacoeconomics; 2010; 28(3):231-54. PubMed ID: 20108995
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delivery of a Nicotine Replacement Therapy Sample at Outdoor Smoking Hotspots for Promoting Quit Attempts: A Pilot Randomized Controlled Trial.
    Cheung YTD; Cheung Li WH; Wang MP; Lam TH
    Nicotine Tob Res; 2020 Aug; 22(9):1468-1475. PubMed ID: 31404466
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness, Cost-effectiveness, and Cost-Utility of a Digital Smoking Cessation Intervention for Cancer Survivors: Health Economic Evaluation and Outcomes of a Pragmatic Randomized Controlled Trial.
    Mujcic A; Blankers M; Boon B; Verdonck-de Leeuw IM; Smit F; van Laar M; Engels R
    J Med Internet Res; 2022 Mar; 24(3):e27588. PubMed ID: 35297777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness of nicotine salt vapes, cytisine, and a combination of these products, for smoking cessation in New Zealand: protocol for a three-arm, pragmatic, community-based randomised controlled trial.
    Walker N; Calder A; Barnes J; Laking G; Parag V; Bullen C
    BMC Public Health; 2023 Sep; 23(1):1760. PubMed ID: 37697327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nicotine replacement therapy sampling for smoking cessation within primary care: results from a pragmatic cluster randomized clinical trial.
    Carpenter MJ; Wahlquist AE; Dahne J; Gray KM; Garrett-Mayer E; Cummings KM; Davis R; Egan BM
    Addiction; 2020 Jul; 115(7):1358-1367. PubMed ID: 31916303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 'Real-world' effectiveness of smoking cessation treatments: a population study.
    Kotz D; Brown J; West R
    Addiction; 2014 Mar; 109(3):491-9. PubMed ID: 24372901
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Financial incentives for quitting smoking in pregnancy: Are they cost-effective?
    McMeekin N; Sinclair L; Robinson-Smith L; Mitchell A; Bauld L; Tappin DM; Boyd KA
    Addiction; 2023 Aug; 118(8):1445-1456. PubMed ID: 36843417
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Promoting smoking cessation in Pakistani and Bangladeshi men in the UK: pilot cluster randomised controlled trial of trained community outreach workers.
    Begh RA; Aveyard P; Upton P; Bhopal RS; White M; Amos A; Prescott RJ; Bedi R; Barton P; Fletcher M; Gill P; Zaidi Q; Sheikh A
    Trials; 2011 Aug; 12():197. PubMed ID: 21854596
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluating the effectiveness of e-cigarettes compared with usual care for smoking cessation when offered to smokers at homeless centres: protocol for a multi-centre cluster-randomized controlled trial in Great Britain.
    Cox S; Bauld L; Brown R; Carlisle M; Ford A; Hajek P; Li J; Notley C; Parrott S; Pesola F; Robson D; Soar K; Tyler A; Ward E; Dawkins L
    Addiction; 2022 Jul; 117(7):2096-2107. PubMed ID: 35194862
    [TBL] [Abstract][Full Text] [Related]  

  • 51. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
    Leaviss J; Sullivan W; Ren S; Everson-Hock E; Stevenson M; Stevens JW; Strong M; Cantrell A
    Health Technol Assess; 2014 May; 18(33):1-120. PubMed ID: 24831822
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Participant Experiences of a Quit Smoking Attempt Through Either Nicotine Replacement Therapy (NRT) Methods or the Use of an E-cigarette.
    Jones G; McIntosh E; Brose LS; Klonizakis M
    J Addict Med; 2022 May-Jun 01; 16(3):272-277. PubMed ID: 34128486
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-Effectiveness Analysis of Smoking Cessation Interventions With Behavioral Support: A Study Based on the Benefits of Smoking Cessation on Outcomes (BENESCO) Model.
    Park SK; Kang DW; Lee EK
    Nicotine Tob Res; 2022 Nov; 24(12):2011-2017. PubMed ID: 35862219
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness, safety and cost-effectiveness of vaporized nicotine products versus nicotine replacement therapy for tobacco smoking cessation in a low-socioeconomic status Australian population: a study protocol for a randomized controlled trial.
    Howard BC; McRobbie H; Petrie D; Barker D; Mendelsohn C; Anderson J; Borland R; Naughton F; Tutka P; Zwar N; Boland VC; Aiken A; Shakeshaft A; Gartner C; Richmond RL; Hall W; Mattick RP; Farrell M; Courtney RJ
    Trials; 2022 Sep; 23(1):777. PubMed ID: 36104702
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden.
    Bolin K; Lindgren B; Willers S
    Chest; 2006 Mar; 129(3):651-60. PubMed ID: 16537864
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT.
    Taylor AH; Thompson TP; Streeter A; Chynoweth J; Snowsill T; Ingram W; Ussher M; Aveyard P; Murray RL; Harris T; Green C; Horrell J; Callaghan L; Greaves CJ; Price L; Cartwright L; Wilks J; Campbell S; Preece D; Creanor S
    Health Technol Assess; 2023 Mar; 27(4):1-277. PubMed ID: 37022933
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors influencing the uptake and use of nicotine replacement therapy and e-cigarettes in pregnant women who smoke: a qualitative evidence synthesis.
    Campbell K; Coleman-Haynes T; Bowker K; Cooper SE; Connelly S; Coleman T
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013629. PubMed ID: 32441810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial.
    Ruger JP; Weinstein MC; Hammond SK; Kearney MH; Emmons KM
    Value Health; 2008; 11(2):191-8. PubMed ID: 17854434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.
    Shaw L; Rodgers H; Price C; van Wijck F; Shackley P; Steen N; Barnes M; Ford G; Graham L;
    Health Technol Assess; 2010 May; 14(26):1-113, iii-iv. PubMed ID: 20515600
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.